Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Sun Pharma Begins Open Offer For Taro at $7.75

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - India's Sun Pharma said its Alkaloida Chemical unit started a tender offer for all shares of Israel's Taro Pharmaceutical as part of a disputed $460 million merger agreement reached a year ago, but unilaterally cancelled by Taro in late May

You may also be interested in...



Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair

MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2

Sun Pharma Extends Offer For Taro Shares In Ongoing Rocky Affair

MUMBAI - Sun Pharmaceutical has extended the tender offer for purchase of all outstanding ordinary shares of Israeli drug maker Taro Pharmaceuticals until September 2

Indian Sectors Spiral Downward While Pharma Remains Best Performer

MUMBAI - Pharma scrips listed on Indian bourses have emerged among the best performers in the downturn that has hit the country's stock markets. The Health Care Index, which is representative of pharma stocks on the Bombay Stock Exchange, has gained 10.2 percent in value over the last year, while most other sectors saw erosion in value from peak levels in June 2007

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel